What this product is for
PLEXUS BRACHIALIS DUO gives practitioners a clearly delimited shoulder–arm field, with a two-step texture sequence that keeps daily routines reproducible.
Where it is applied
The zones listed below (application field) are the possible application areas. The product can be applied across all of these zones, or more specifically in one or several of them, in consultation with your practitioner.
Application field: shoulder-arm.
How to use it
- 01Bring 1 push (airless system) of phase 1 to the area indicated by your therapist or in the application zones specific for this product.
- 02Apply the product 2 times a day in this selected area, in a thin layer.
- 03Follow up by phase 2 of this product if indicated by your therapist, following the steps in the application sequence.
Application sequence
Phase 1 · Week 1–2, 1–2 applications per day
Nerve release
The first texture is applied thinly over the lower shoulder girdle and below the armpit, then over the upper arm and under arm in the skin field of the affected nerve, and finally along the nerve paths towards the fingertips. Zone order stays identical at every session.
Phase 2 · Two minutes after phase 1
Nerve integration
After a two-minute pause the second, lighter texture is applied over the identical field in the same order. From week 3 the morning application uses phase 2 and the evening phase 1; from week 4 onwards phase 2 is used.
What is in it
Ingredients are listed by name and function. Composition quantities are part of the controlled manufacturing documentation and are not published on this page.
Lanette cream FNA
The emulsion base of both phases; carries every other constituent evenly over the application zone.
Aqua purificataAqua
Sets the water phase that determines spreadability across the defined surface field.
Magnesium chloride
Documented mineral constituent of both phases, dissolved in the water phase.
MSMDimethyl sulfone
Documented sulphur constituent of both phases, kept at a level that keeps the texture light.
Palmitoylethanolamide (PEA)
Documented lipid constituent, separately dispersed before it enters the base.
Boswellia serrata
Documented botanical constituent of both phases.
Hypericum perforatum D6Hypericum Perforatum
Documented homeopathic addition in D6 dilution in both phases.
Ginkgo biloba
Documented botanical constituent of the release phase.
Ruta graveolens
Documented constituent of the release phase only.
Arnica oilPrunus Amygdalus Dulcis Oil, Arnica Montana Flower Extract
Organic Arnica montana flower macerate in cold-pressed sweet almond oil; documented constituent of phase 1 only.
Bacopa monnieri
Documented constituent of the integration phase only.
Blue Lotus (Nymphaea caerulea)
Documented constituent of the integration phase only.
Copaiba
Documented oleoresin constituent, added late in the process at low temperature.
α-BisabololBisabolol
Documented dermal constituent of both phases.
Betaine (TMG)Betaine
Documented humectant constituent of both phases.
D-PanthenolPanthenol
Documented conditioning constituent; contributes to a smooth, non-tacky finish.
Vitamin ETocopherol
Protects the lipid fraction so successive batches stay comparable.
Silicea Gel
Documented mineral gel constituent of the water phase.
COSGARDBenzyl alcohol, dehydroacetic acid
Preservation system that keeps the composition stable over its stated period of use.
Safety
- For external cutaneous topical application on intact skin only.
- Avoid contact with the eyes, mucous membranes and broken or irritated skin.
- Discontinue use if irritation occurs and consult your practitioner.
- Keep out of reach of children.
- This is a cutaneous topical composition. It is not a medicine and makes no therapeutic claim.
Storage
Store closed and upright, away from direct sunlight and heat. Use within the period stated on the package.
Questions
Is this a medicinal product?
No. SIRIAM formulations are cutaneous topical compositions. They are described by application region and composition, not directed at a therapeutic indication but rather at regulation of the nervous system. EMG validation will need to support this further in the future.
Who determines the application region?
The region is identified by a healthcare professional using anatomical landmarks and surface maps. Our documentation supports that conversation.
Can the formulation be combined with other routines?
Combination and sequencing are decided together with the treating professional. We document composition, application and response.
Record reference
- Product ID
- SIR-PBR-01
- Family
- PLEXUS
- Version
- 1.3
- Batch
- PBR-2512
- Updated
- 2025-12
- Published by
- SIRIAM LAB